MX365029B - Biomarcadores de lesion renal. - Google Patents
Biomarcadores de lesion renal.Info
- Publication number
- MX365029B MX365029B MX2013003321A MX2013003321A MX365029B MX 365029 B MX365029 B MX 365029B MX 2013003321 A MX2013003321 A MX 2013003321A MX 2013003321 A MX2013003321 A MX 2013003321A MX 365029 B MX365029 B MX 365029B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- kidney disease
- long
- recovery
- term dialysis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38623010P | 2010-09-24 | 2010-09-24 | |
| US13/235,005 US10557856B2 (en) | 2010-09-24 | 2011-09-16 | Biomarkers of renal injury |
| PCT/US2011/052082 WO2012040073A2 (en) | 2010-09-24 | 2011-09-19 | Biomarkers of renal injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013003321A MX2013003321A (es) | 2013-10-25 |
| MX365029B true MX365029B (es) | 2019-05-21 |
Family
ID=45871234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003321A MX365029B (es) | 2010-09-24 | 2011-09-19 | Biomarcadores de lesion renal. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10557856B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2619577B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5998143B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR101981745B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN103189745B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2011305786B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112013006935B1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2811658C (cg-RX-API-DMAC10.html) |
| EA (1) | EA030622B1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX365029B (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ608384A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2012040073A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107233337A (zh) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| MX377553B (es) | 2009-04-29 | 2025-03-10 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
| BRPI1011883A2 (pt) | 2009-06-15 | 2016-09-13 | Amarin Pharma Inc | uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina |
| NZ599061A (en) | 2009-09-23 | 2014-05-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20130282390A1 (en) * | 2012-04-20 | 2013-10-24 | International Business Machines Corporation | Combining knowledge and data driven insights for identifying risk factors in healthcare |
| US20130330829A1 (en) * | 2012-06-06 | 2013-12-12 | The Cleveland Clinic Foundation | Prediction of acute kidney injury from a post-surgical metabolic blood panel |
| ES3059226T3 (en) * | 2012-10-08 | 2026-03-19 | Vifor Int Ltd | Potassium-binding agents for treating hypertension and hyperkalemia |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| ES2836127T3 (es) * | 2013-03-15 | 2021-06-24 | Sera Prognostics Inc | Biomarcadores y métodos para predecir el parto prematuro |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US10126305B2 (en) | 2013-06-25 | 2018-11-13 | University of Pittsburg—Of the Commonwealth System of Higher Education | Proteomic biomarkers of sepsis in elderly patients |
| GB201317621D0 (en) * | 2013-10-04 | 2013-11-20 | Randox Teoranta | Kidney disease biomarker |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| EP3254115A4 (en) * | 2015-02-05 | 2018-06-20 | University of Florida Research Foundation, Inc. | Use of nhe3 as biomarker for radiation biodosimetry |
| EP3196791A1 (de) * | 2017-05-02 | 2017-07-26 | Siemens Healthcare GmbH | Verfahren zur unterstützung von medizinischem personal, unterstützungssystem, computerprogramm und datenträger |
| JP7344127B2 (ja) | 2017-05-31 | 2023-09-13 | マース インコーポレーテッド | 慢性腎臓病の診断及び治療方法 |
| AU2018313853A1 (en) * | 2017-08-08 | 2020-01-02 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| CA3089817A1 (en) | 2018-01-19 | 2019-07-25 | Mars, Incorporated | Biomarkers and classification algorithms for chronic kidney disease in cats |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| US20190317090A1 (en) * | 2018-04-12 | 2019-10-17 | Children's Hospital Medical Center | Compositions and methods for forecasting response to lupus nephritis (ln)therapy |
| WO2020006571A1 (en) * | 2018-06-29 | 2020-01-02 | pulseData Inc. | Machine learning systems and methods for predicting risk of renal function decline |
| JP7633147B2 (ja) | 2018-07-14 | 2025-02-19 | マース インコーポレーテッド | 慢性腎臓病のためのバイオマーカー及びテストモデル |
| MA50490A (fr) | 2018-09-24 | 2020-09-02 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| CN109754878B (zh) * | 2018-11-30 | 2023-06-20 | 平安科技（深圳）有限公司 | 慢性肾病筛查方法、装置、设备及存储介质 |
| CN109738931B (zh) * | 2018-12-18 | 2022-06-17 | 上海瑞派益尔科技有限公司 | 一种肾小球滤过率检测设备 |
| US11350887B2 (en) | 2019-08-07 | 2022-06-07 | Fresenius Medical Care Holdings, Inc. | Systems and methods for detection of potential health issues |
| CN110596370B (zh) * | 2019-09-17 | 2023-03-24 | 广州医科大学附属第五医院 | 一种检测细菌尿路感染的酶联免疫吸附试剂盒及其应用 |
| CA3160676A1 (en) | 2019-11-12 | 2021-05-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| CN110923310B (zh) * | 2019-12-24 | 2023-04-18 | 广州市妇女儿童医疗中心 | 用于指导肾病综合征cyp3a5表达型患儿使用他克莫司的多态性位点 |
| CN110904219B (zh) * | 2019-12-24 | 2023-04-18 | 广州市妇女儿童医疗中心 | Myh9及ctla4基因多态性位点在指导肾病综合征患儿使用他克莫司中的应用 |
| WO2021247550A1 (en) | 2020-06-01 | 2021-12-09 | Mars, Incorporated | System and method for chronic kidney disease of a dog |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| RU2761738C1 (ru) * | 2021-06-07 | 2021-12-13 | Алина Владимировна Еремеева | Способ отбора детей с дебютом острого пиелонефрита для проведения курса противорецидивной терапии пиелонефрита |
| WO2022261513A1 (en) * | 2021-06-10 | 2022-12-15 | Kang Zhang | Methods and systems of detecting and predicting chronic kidney disease and type 2 diabetes using deep learning models |
| WO2024040225A2 (en) * | 2022-08-19 | 2024-02-22 | The Johns Hopkins University | Diagnosis and treatment of acute kidney injury |
| TW202515633A (zh) * | 2023-06-28 | 2025-04-16 | 美商阿比奥梅德公司 | 心腎綜合症（ｃｒｓ）治療系統和方法 |
| CN117373584B (zh) * | 2023-12-08 | 2024-03-12 | 北京大学第一医院 | 一种急性肾损伤的动态预测方法及系统 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| CA2072758A1 (en) | 1990-09-14 | 1992-03-15 | Kenneth Francis Buechler | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| AU1772992A (en) | 1991-04-10 | 1992-11-17 | Biosite Diagnostics Incorporated | Crosstalk inhibitors and their uses |
| EP0579767B1 (en) | 1991-04-11 | 2000-08-23 | Biosite Diagnostics Inc. | Novel conjugates and assays for simultaneous detection of multiple ligands |
| US6019944A (en) | 1992-05-21 | 2000-02-01 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6350571B1 (en) | 1996-02-01 | 2002-02-26 | Vinata B. Lokeshwar | Methods for detection and evaluation of bladder cancer |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| CN101393165A (zh) * | 2007-09-20 | 2009-03-25 | 复旦大学附属华山医院 | 一种检测糖尿病肾病血清标本中差异表达的蛋白质谱的方法 |
| CN101960308B (zh) * | 2008-02-29 | 2014-07-09 | 国立大学法人名古屋大学 | 急性肾损伤及预后推测用生物标记物以及其用途 |
| US20090239242A1 (en) | 2008-03-18 | 2009-09-24 | Biotrin Intellectual Properties Limited | Method for the early identification and prediction of kidney injury |
| JP2012501456A (ja) * | 2008-08-28 | 2012-01-19 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| CA2735590A1 (en) * | 2008-08-29 | 2010-03-04 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US8501489B2 (en) | 2008-09-26 | 2013-08-06 | University of Pittsburgh—of the Commonwealth System of Higher Education | Urinary biomarkers to predict long-term dialysis |
| EP2767833A3 (en) * | 2008-10-21 | 2014-12-17 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2364370B1 (en) * | 2008-11-22 | 2014-09-03 | Astute Medical, Inc. | Methods for prognosis of acute renal failure |
| US20120315649A1 (en) * | 2009-08-28 | 2012-12-13 | Astute Medical ,Inc. a corporation | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| MX342967B (es) * | 2009-12-20 | 2016-10-19 | Astute Medical Inc | Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal. |
-
2011
- 2011-09-16 US US13/235,005 patent/US10557856B2/en active Active
- 2011-09-19 KR KR1020137009232A patent/KR101981745B1/ko not_active Expired - Fee Related
- 2011-09-19 WO PCT/US2011/052082 patent/WO2012040073A2/en not_active Ceased
- 2011-09-19 NZ NZ608384A patent/NZ608384A/en not_active IP Right Cessation
- 2011-09-19 MX MX2013003321A patent/MX365029B/es active IP Right Grant
- 2011-09-19 EP EP11827278.0A patent/EP2619577B1/en active Active
- 2011-09-19 JP JP2013530205A patent/JP5998143B2/ja active Active
- 2011-09-19 CN CN201180053315.7A patent/CN103189745B/zh active Active
- 2011-09-19 BR BR112013006935-0A patent/BR112013006935B1/pt not_active IP Right Cessation
- 2011-09-19 CA CA2811658A patent/CA2811658C/en active Active
- 2011-09-19 EA EA201390439A patent/EA030622B1/ru not_active IP Right Cessation
- 2011-09-19 AU AU2011305786A patent/AU2011305786B2/en active Active
-
2020
- 2020-01-15 US US16/743,610 patent/US11693014B2/en active Active
-
2023
- 2023-05-22 US US18/321,405 patent/US12601746B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012040073A3 (en) | 2012-06-14 |
| US12601746B2 (en) | 2026-04-14 |
| AU2011305786A1 (en) | 2013-04-11 |
| US10557856B2 (en) | 2020-02-11 |
| BR112013006935A2 (pt) | 2017-05-30 |
| EP2619577A2 (en) | 2013-07-31 |
| WO2012040073A2 (en) | 2012-03-29 |
| US20240118289A1 (en) | 2024-04-11 |
| CN103189745A (zh) | 2013-07-03 |
| JP2013539030A (ja) | 2013-10-17 |
| MX2013003321A (es) | 2013-10-25 |
| KR20140001863A (ko) | 2014-01-07 |
| EP2619577A4 (en) | 2014-04-30 |
| EA201390439A1 (ru) | 2013-09-30 |
| AU2011305786B2 (en) | 2015-04-23 |
| BR112013006935B1 (pt) | 2021-02-23 |
| KR101981745B1 (ko) | 2019-05-27 |
| US11693014B2 (en) | 2023-07-04 |
| CA2811658A1 (en) | 2012-03-29 |
| CN103189745B (zh) | 2018-05-01 |
| EA030622B1 (ru) | 2018-09-28 |
| CA2811658C (en) | 2021-03-30 |
| US20120077690A1 (en) | 2012-03-29 |
| US20200150132A1 (en) | 2020-05-14 |
| EP2619577B1 (en) | 2017-08-16 |
| JP5998143B2 (ja) | 2016-09-28 |
| NZ608384A (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012040073A3 (en) | Biomarkers of renal injury | |
| Wittens et al. | Editor's choice–management of chronic venous disease: clinical practice guidelines of the European Society for Vascular Surgery (ESVS) | |
| CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
| EP3761034A3 (en) | Urine biomarkers for prediction of recovery after acute kidney injury: proteomics | |
| BR112015014510A2 (pt) | agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais | |
| CO2017005599A2 (es) | Composición que comprende glucomanano, carragenina, goma xantano y una sal de catión monovalente o divalente | |
| BR112013017745A2 (pt) | métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho | |
| MX382244B (es) | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales | |
| MX2017009694A (es) | Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l). | |
| BR112015028307A2 (pt) | método de produção de membranas de poliimida | |
| BR112015022825A2 (pt) | métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos | |
| BR112015017241A2 (pt) | doadores de nitroxil com índice terapêutico melhorado | |
| Peng et al. | Jackknife empirical likelihood method for some risk measures and related quantities | |
| EP3695841A3 (en) | Ship inhibition to combat obesity | |
| PT4324522T (pt) | Métodos de tratamento de pacientes com fabry tendo insuficiência renal | |
| BR112014019274A2 (pt) | métodos relacionados ao tratamento de doenças e distúrbios inflamatórios | |
| KIM et al. | The risk factors of delirium in orthopedic elderly patients | |
| Vera et al. | Risk factors for intraoperative hypertension during surgery for primary hyperparathyroidism | |
| Silva et al. | Clipagem microcirúrgica de aneurismas cerebrais de circulação anterior: estudo de uma série pessoal e revisão crítica da literatura | |
| IN2014DN09640A (cg-RX-API-DMAC10.html) | ||
| Ruihua | Measures of Health-related Quality of Life in Huge Ameloblastoma Young Patients after Mandible Reconstruction with Free Fibula Flap | |
| BR112013025113A2 (pt) | composições e métodos para tratamento, diagnóstico e monitoramento de doenças | |
| LI | Risk factors and clinical features of intra-procedural rupture in endovascular treatment of unruptured intracranial aneurysm | |
| LIN et al. | Risk factors for surgical site infections after spine surgery | |
| YANG et al. | Perioperative management and risk factors affecting the prognosis of hip fracture surgery in elderly patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |